Oral anticoagulant
IDENTIFICATION OF ADVERSE REACTIONS TO ORAL ANTICOAGULANT THERAPY IN HOSPITALIZED PATIENTS: A DESCRIPTIVE STUDY
... with oral anticoagulants, such as warfarin ...on oral anticoagulant therapy were monitored by means of the prothrombin time (PT), as expressed by the International Normalized Ratio (INR) (reference ...
5
Quality of Life analysis of patients in chronic use of oral anticoagulant: an observational study
... The oral anticoagulant therapy control is complex and requires frequent analytical checking, with several visits to health units to control the INR (International Nor- malized ...of oral ...
6
Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement
... antagonist oral anticoagulant; OEGARI: Austrian Society of Anaesthesiology, Resuscitation and Intensive Care Medicine; PCC: Prothrombin complex concentrate; PFA: Platelet function analyzer; PT: Prothrombin ...
16
Personalized versus non personalized computerized decision support system to increase therapeutic quality control of oral anticoagulant therapy: an alternating time series analysis
... Background: The quality control of oral anticoagulant therapy (OAT) during the initiation and maintenance treatment is generally poor. Physicians' ordering of OAT (especially fluindione and warfarin) can be ...
8
Spontaneous Hemothorax Due to Oral Anticoagulant Therapy
... Oral anticoagulant treatment is widely used in many diseases, with warfarin being the most commonly used active ...an oral anticoagulant, a chest tube was not inserted in the patient and ...
5
Should oral anticoagulant therapy be continued during dental extraction? A meta-analysis
... continuing oral anticoagulant therapy do not have an in- creased risk of bleeding after dental extraction compared to patients who discontinue oral anticoagulant ...
9
“Knowledge of, Satisfaction with and Adherence to Oral Anticoagulant Drugs among Patients in King Fasial Hospital; Taif, Kingdom of Saudi Arabia” by Dr. Abubaker Ibrahim Elbur, Dr. Ahmed Abdulrahman Albarraq, Dr. Mohammed M. Maugrabi, Sultan Abdullah Alharthi, Kingdom of Saudi Arabia.
... to oral anticoagulant treatment are important measures that decrease morbidity and ...to oral anticoagulant treatment and to identify predictors of the three studied ...on oral ...
7
Effects of computer-assisted oral anticoagulant therapy
... computer-assisted oral anticoagulant therapies to improve the time to reach and the time in the TTR com- pared to traditional oral anticoagulant therapy by physi- ...
7
Electronic Counselling for Oral Anticoagulant Patients
... Novel oral anticoagulants or new oral anticoagulants (NOACs), non-vitamin K antagonist oral anticoagulants (NOACs), target-specific oral anticoagulant agents (TSOACs), or direct ...
210
Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients
... (oral anticoagulant dose, compounding medication) and clinical parameters (accompanying disorders and diseases), which seems very intriguing, it needs to be emphasized that our opinion presented in this ...
10
Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
... new oral anticoagulant has some major advantages over traditional anticoagulants, includ- ing a lack of need for anticoagulant monitoring and a low drug–drug interaction potential, and can be used in ...
5
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
... the anticoagulant activity of FXa inhibitors and, hence, reversal, despite the wide availabil- ity and ease of these ...with anticoagulant activity and reversal but is an impractical method, particularly in ...
10
Bleeding complications in oral anticoagulant therapy: an analysis of risk factors
... To establish the mdependent mfluence of vanous pos- sible nsk factors for the occurrence of bleeding (age, sex, target zone, coumarm derivative used, and the achieved mtensity of anticoa[r] ...
6
Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program
... acting oral anticoagulants (DOAC) into clinical practice over the past decade has dramatically changed the field of stroke and thrombosis prevention and ...traditional anticoagulant treatment in a variety ...
9
Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants
... Our data, with the limitation of a relatively small but well- selected sample of patients with oral anticoagulation installed for secondary stroke prevention, show that overall adherence to OAT is strong (90%). ...
11
Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era
... novel oral anticoagulants (NOACs) dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct Factor Xa inhibitors) have been developed as treatment alternatives to ...
12
Vitamin K and stability of oral anticoagulant therapy
... 39 of those patients had stopped their anticoagulant drug or had been given vitamin K and were censored in the analysis. At 8 weeks 14% of patients had had a low INR and at 16 weeks this was 23%. Figure 2 shows ...
111
Towards improvement of oral anticoagulant therapy
... the anticoagulant effect by measurements of the International Normalised Ratio (INR) with adjustment of anticoagulant dose is required to maintain patients within the therapeutic ...optimal ...
155
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
... direct oral anticoagulants, such as rivaroxaban, apixaban, and dabigatran, in preference to vitamin K antagonist therapy for the prevention of stroke in patients with ...for anticoagulant therapy in this ...
9
BETRIXABAN – THE FIRST AND ONLY ORAL ANTICOAGULANT APPROVED FOR VTE
... Betrixaban is derived from 1,N-(5-chloropyridin-2-yl)-2- (4-(N, N-dimethylcarbamimidoyl)-benzamido) benzamide, which is an anthranilamide- based compound with potent factor Xa activity. Although several selected ...
8